Incidence of second primary malignancies (SPMs) in patients in the US with triple-class-exposed (TCE) relapsed or refractory multiple myeloma (RRMM)

被引：0
|
作者：
Ge, Wenzhen [1 ]
Archambault, Alexi [2 ]
Delea, Thomas E. [3 ]
Lorenc, Karen Rodriguez [2 ]
Harnett, James [2 ]
Moynahan, Aaron P. [3 ]
Weycker, Derek [3 ]
Houvras, Yariv [2 ]
Kroog, Glenn S. [2 ]
Wu, Ning [2 ]
Hampp, Christian [2 ]
Ma, Qiufei [2 ]
Ailawadhi, Sikander [4 ]
机构：
[1] Regeneron Pharmaceut, Tarrytown, NY USA
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Policy Anal Inc PAI, Cambridge, MA USA
[4] Mayo Clin, Rochester, MN USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
182
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [1] Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
    Ge, Wenzhen
    Archambault, Alexi
    Delea, Thomas E.
    Lorenc, Karen Rodriguez
    Harnett, James
    Moynahan, Aaron
    Weycker, Derek
    Houvras, Yariv
    Kroog, Glenn S.
    Wu, Ning
    Hampp, Christian
    Ma, Qiufei
    [J]. BLOOD, 2022, 140 : 10897 - 10899
  • [2] Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Ailawadhi, Sikander
    Delea, Thomas
    Moynahan, Aaron
    Ge, Wenzhen
    Hampp, Christian
    Archambault, Alexi
    Wu, Ning
    Lorenc, Karen Rodriguez
    Noguera-Troise, Irene
    Kroog, Glenn S.
    Houvras, Yariv
    Ma, Qiufei
    [J]. BLOOD, 2023, 142
  • [3] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Jagannath, Sundar
    Lee, Hans C.
    Richter, Joshua Ryan
    Zonder, Jeffrey A.
    Hoffman, James E.
    Zhou, Zheng-Yi
    Horton, Viviana Garcia
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Qiufei
    Inocencio, Timothy J.
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn Scott
    Rodriguez-Lorenc, Karen
    Houvras, Yariv
    Bumma, Naresh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis
    Patel, Krina
    Rodriguez-Otero, Paula
    Manier, Salomon
    Baz, Rachid
    Raab, Marc
    Cavo, Michele
    Callander, Natalie
    Costa, Luciano
    Moreau, Philippe
    Solomon, Scott
    Chen, Christine
    Raje, Noopur
    Scheid, Christoph
    Delforge, Michel
    Larsen, Jeremy
    Pabst, Thomas Mueller
    Suzuki, Kenshi
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Giralt, Sergio
    Mateos, Maria-Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S56 - S57
  • [6] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
    Manier, Salomon
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Einsele, Hermann
    Bahlis, Nizar
    Munshi, Nikhil
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Nooka, Ajay
    Vij, Ravi
    Abrahamsen, Ingerid Weum
    Broijl, Annemiek
    Jagannath, Sundar
    Benjamin, Reuben
    Gergis, Usama
    Sborov, Douglas
    Iida, Shinsuke
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Bhatnagar, Rashmi
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Baz, Rachid
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S50 - S51
  • [7] CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhou, J.
    Burnett, J.
    Zheng, X.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    Wu, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S82 - S82
  • [8] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
    Patel, Krina
    Rodriguez-Otero, Paula
    Manier, Salomon
    Baz, Rachid
    Raab, Mark-Steffen
    Cavo, Michele
    Callander, Natalie
    Costa, Luciano J.
    Moreau, Phillippe
    Solomon, Scott
    Chen, Christine
    Raje, Noopur
    Scheid, Christoph
    Delforge, Michel
    Larsen, Jeremy
    Pabst, Thomas
    Suzuki, Kenshi
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Giralt, Sergio
    Mateos, Maria-Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S498
  • [9] Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
    Einsele, Hermann
    Rodriguez-Otero, Paula
    Arnulf, Bertrand
    Patel, Krina
    Manier, Salomon
    Costa, Luciano
    Bahlis, Nizar
    Broijl, Annemiek
    Chen, Christine
    Abrahamsen, Ingerid Weum
    Delforge, Michel
    Gergis, Usama
    Raab, Marc
    Singhal, Seema
    Abonour, Rafat
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Felten, Jasper
    Caia, Andrea
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Ailawadhi, Sikander
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S37 - S37
  • [10] Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
    Rodriguez Otero, Paula
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina K.
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie S.
    Costa, Luciano
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Abrahamsen, Ingerid Weum
    Baz, Rachid
    Broijl, Annemiek
    Chen, Christine
    Jagannath, Sundar
    Raje, Noopur S.
    Scheid, Christof
    Delforge, Michel
    Benjamin, Reuben
    Pabst, Thomas
    Iida, Shinsuke
    Berdeja, Jesus G.
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Wu, Fan
    Piasecki, Julia
    Eliason, Laurie
    Dhanda, Devender
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Popa-McKiver, Mihaela
    Giralt, Sergio A.
    [J]. BLOOD, 2023, 142
12345